Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

Completed · Phase 3 · Has a placebo group

Conditions studied: Bronchiectasis

In brief

The purpose of this study is to evaluate if the time to first pulmonary exacerbation of bronchiectasis or its frequency can be prolonged by inhalation of ciprofloxacin for 28 days every other 28 days or for 14 days every other 14 days over 48 weeks.

Key facts

Study ID

NCT02106832

Run by

Bayer

People needed

521

Starts

2014-04-30

Expected to finish

2016-10-19

Last updated by the study team

2017-10-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with a proven and documented diagnosis of non CF idiopathic or post infectious bronchiectasis
• Stable pulmonary status and stable regimen of standard treatment at least for the past 4 weeks

You may not qualify if…

• Forced expiratory volume in 1 second (FEV1) <30% or >90% predicted
• Active allergic bronchopulmonary aspergillosis
• Active and actively treated non tuberculosis mycobacterial (NTM) infection or tuberculosis
• Primary diagnosis of Chronic obstructive pulmonary disease (COPD)

Where it is running

• Study site — Fountain Valley, California, United States
• Study site — La Jolla, California, United States
• Study site — Long Beach, California, United States
• Study site — Newport Beach, California, United States
• Study site — San Diego, California, United States
• Study site — Kissimmee, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Sarasota, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — Decatur, Georgia, United States
• Study site — Skokie, Illinois, United States
• Study site — Olathe, Kansas, United States
• Study site — Rochester, Minnesota, United States
• Study site — Brooklyn, New York, United States
• Study site — Mineola, New York, United States
• Study site — Asheville, North Carolina, United States
• Study site — Portland, Oregon, United States
• Study site — Doylestown, Pennsylvania, United States
• Study site — Greenville, South Carolina, United States
• Study site — Edinburg, Texas, United States
• Study site — Tyler, Texas, United States
• Study site — Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
• Study site — Capital Federal, Ciudad Auton. de Buenos Aires, Argentina
• Study site — Godoy Cruz, Mendoza Province, Argentina
• Study site — Peoria, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.